- CORE D Core D offers world-class genomics and proteomics services to the members of the Program. The Next Generation sequencing facility was strongly supported by CSHL during the last five years, and it has extended its capability in short (Illumina HiSeq2500, MiSeq and NextSeq) and long read technologies (Pacific Biosciences, Oxford Nanopore). Core D offers an extensive array of sequencing applications, including but not limited to RNA- Seq, Iso-Seq, whole genome sequencing, targeted sequencing (exomes, gene set, and amplicons), ChIP-Seq and single-cell sequencing. For proteomics, the Core offers protein identification, protein complex identification following IP, quantitative proteomics with iTRAQ and a panel of small molecule and metabolite screens. The Core will continue working with members to develop new sequencing and proteomics applications, including in the area of long sequencing reads and single-cell sequencing, The Core will also offer experimental design support, sequencing project management and sequencing QC analysis to the investigators.
- CORE D Genomics and proteomic are essential tools in cancer research. Core D provides services in DNA sequencing to identify changes in gene expression, epigenetics and DNA mutations driving the growth and maintenance of cancer. Mass spectrometry identifies proteins bound to essential cellular complexes, deepening our understanding of cancer cell growth and gene regulation.
| On, Kin Fan; Jaremko, Matt; Stillman, Bruce et al. (2018) A structural view of the initiators for chromosome replication. Curr Opin Struct Biol 53:131-139 |
| Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381 |
| Shamay, Yosi; Shah, Janki; I??k, Mehtap et al. (2018) Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater 17:361-368 |
| Tramentozzi, Elisa; Ferraro, Paola; Hossain, Manzar et al. (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102-1114 |
| Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277 |
| Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6 |
| Xu, Yali; Milazzo, Joseph P; Somerville, Tim D D et al. (2018) A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Cancer Cell 33:13-28.e8 |
| Huang, Yu-Han; Klingbeil, Olaf; He, Xue-Yan et al. (2018) POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915-928 |
| Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7: |
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
Showing the most recent 10 out of 610 publications
